Principal Financial Group Inc Exelixis, Inc. Transaction History

Principal Financial Group Inc

  • $172 Billion
  • Q3 2024

A detailed history of Principal Financial Group Inc transactions in Exelixis, Inc. stock. As of the latest transaction made, Principal Financial Group Inc holds 665,742 shares of EXEL stock, worth $23.1 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
665,742
Previous 972,690 31.56%
Holding current value
$23.1 Million
Previous $21.9 Million 20.96%
% of portfolio
0.01%
Previous 0.01%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 31, 2024
SELL
$21.96 - $27.6 $6.74 Million - $8.47 Million
-306,948 Reduced 31.56%
665,742 $17.3 Million
Q2 2024

Jul 29, 2024
SELL
$20.34 - $23.73 $3.53 Million - $4.12 Million
-173,467 Reduced 15.13%
972,690 $21.9 Million
Q1 2024

Apr 29, 2024
SELL
$20.17 - $23.93 $116,622 - $138,363
-5,782 Reduced 0.5%
1,146,157 $27.2 Million
Q4 2023

Feb 07, 2024
SELL
$19.25 - $24.13 $665,530 - $834,246
-34,573 Reduced 2.91%
1,151,939 $27.6 Million
Q3 2023

Nov 02, 2023
SELL
$19.04 - $22.74 $910,302 - $1.09 Million
-47,810 Reduced 3.87%
1,186,512 $25.9 Million
Q2 2023

Aug 07, 2023
SELL
$18.17 - $20.48 $904,030 - $1.02 Million
-49,754 Reduced 3.87%
1,234,322 $23.6 Million
Q1 2023

May 09, 2023
BUY
$16.3 - $19.41 $177,001 - $210,773
10,859 Added 0.85%
1,284,076 $24.9 Million
Q4 2022

Feb 09, 2023
BUY
$14.96 - $17.39 $260,184 - $302,446
17,392 Added 1.38%
1,273,217 $20.4 Million
Q3 2022

Nov 09, 2022
SELL
$15.68 - $22.27 $251,507 - $357,210
-16,040 Reduced 1.26%
1,255,825 $19.7 Million
Q2 2022

Aug 10, 2022
BUY
$17.44 - $23.16 $3.42 Million - $4.54 Million
196,160 Added 18.24%
1,271,865 $26.5 Million
Q1 2022

May 09, 2022
SELL
$17.03 - $22.67 $169,295 - $225,362
-9,941 Reduced 0.92%
1,075,705 $24.4 Million
Q4 2021

Feb 09, 2022
SELL
$15.84 - $21.88 $151,652 - $209,479
-9,574 Reduced 0.87%
1,085,646 $19.8 Million
Q3 2021

Nov 09, 2021
SELL
$16.3 - $21.14 $32,811 - $42,554
-2,013 Reduced 0.18%
1,095,220 $23.2 Million
Q2 2021

Aug 10, 2021
BUY
$17.95 - $25.56 $361,333 - $514,522
20,130 Added 1.87%
1,097,233 $20 Million
Q1 2021

May 10, 2021
BUY
$20.53 - $25.22 $3.11 Million - $3.83 Million
151,703 Added 16.39%
1,077,103 $24.3 Million
Q4 2020

Feb 08, 2021
BUY
$18.39 - $24.8 $49,174 - $66,315
2,674 Added 0.29%
925,400 $18.6 Million
Q3 2020

Nov 06, 2020
SELL
$20.67 - $26.94 $555,216 - $723,635
-26,861 Reduced 2.83%
922,726 $22.6 Million
Q2 2020

Aug 05, 2020
BUY
$16.46 - $27.42 $309,711 - $515,934
18,816 Added 2.02%
949,587 $22.5 Million
Q1 2020

May 12, 2020
SELL
$14.46 - $21.8 $5.61 Million - $8.46 Million
-387,956 Reduced 29.42%
930,771 $16 Million
Q4 2019

Feb 05, 2020
BUY
$15.15 - $18.89 $41,632 - $51,909
2,748 Added 0.21%
1,318,727 $23.2 Million
Q3 2019

Nov 13, 2019
SELL
$17.68 - $22.65 $350,629 - $449,194
-19,832 Reduced 1.48%
1,315,979 $23.3 Million
Q2 2019

Aug 12, 2019
BUY
$18.93 - $24.75 $74,584 - $97,515
3,940 Added 0.3%
1,335,811 $28.5 Million
Q1 2019

May 10, 2019
BUY
$19.6 - $24.76 $279,594 - $353,201
14,265 Added 1.08%
1,331,871 $31.7 Million
Q4 2018

Feb 14, 2019
SELL
$13.65 - $21.8 $299,521 - $478,357
-21,943 Reduced 1.64%
1,317,606 $25.9 Million
Q3 2018

Nov 14, 2018
BUY
$15.87 - $22.4 $1.38 Million - $1.95 Million
87,093 Added 6.95%
1,339,549 $23.7 Million
Q2 2018

Aug 13, 2018
BUY
$18.56 - $22.45 $21.6 Million - $26.1 Million
1,161,450 Added 1276.23%
1,252,456 $0
Q1 2018

May 14, 2018
BUY
$22.15 - $31.89 $98,456 - $141,751
4,445 Added 5.14%
91,006 $2.02 Million
Q4 2017

Feb 13, 2018
BUY
$24.23 - $30.93 $919,916 - $1.17 Million
37,966 Added 78.13%
86,561 $2.63 Million
Q3 2017

Nov 02, 2017
BUY
$23.35 - $29.24 $1.13 Million - $1.42 Million
48,595
48,595 $1.18 Million

Others Institutions Holding EXEL

# of Institutions
500
Shares Held
244M
Call Options Held
2.54M
Put Options Held
2.29M
View Full List

About EXELIXIS, INC.

EXEL Quotes by TradingView
  • Ticker EXEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 321,832,000
  • Market Cap $11.2B
  • Description
  • Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...
More about EXEL
Track This Portfolio

Track Principal Financial Group Inc Portfolio

Follow Principal Financial Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Principal Financial Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Principal Financial Group Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email